Adalimumab, placebo both lead to improvements in bladder pain

07/10/2013 | Medscape (free registration)

A proof-of-concept study in the Journal of Urology found adalimumab was linked to gains in all measures of interstitial cystitis/bladder pain syndrome, but did not perform better than placebo therapy. Researchers from Palomar Medical Center in California stopped the study early when 53% of the 43 patients showed significant improvements, along with 50% of patients in the placebo group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care